Bionx' SmartScrew cannulated fracture management screw among five new products pending at FDA.
This article was originally published in The Gray Sheet
Executive Summary
BIONX IMPLANTS' SMARTSCREW CANNULATED FRACTURE MANAGEMENT SCREW for treatment of Colles fractures of the wrist is one of five new orthopedic products for which recent 510(k) submissions are currently pending at FDA, Bionx President and CEO David Anderson told the BancAmerica Robertson Stephens conference Dec. 1 in New York City. Cannulation of the screw is intended to facilitate surgery through visualization "under a C-arm or under fluoroscopy," Anderson explained.